MYC and lymphoma: One of the earliest proof of concept experiments used a vector expressing both Cas9 and an sgRNA against Trp53. When established Eμ-Myc p19ARF-/- lymphomas were transduced and transplanted into recipients, lymphoma growth in vivo was accelerated (138).